Nektar Therapeutics (NKTR) has an average rating of buy and mean price target of $130.62, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Price: $104.82, Change: $+19.96, Percent Change: +23.52%
Major digital assets rose Friday, with Bitcoin (BTC-USD) exceeding the $77,000 level.The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, rose 2.3% in the past 24 hours. The Nasdaq 100 gained 1.2%, the S&P 500 increased 1.1%, and the Dow Jones Industrial Average climbed up 1.8%.Bitcoin rose 2.8% to $77,353, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume surged 28.9% to $54.38 billion.Ethereum (ETH-USD), the second-largest digital asset by market value, gained 3.2% to $2,430.XRP (XRP-USD) climbed 1.8%, BNB (BNB-USD) rose 0.8%, while Solana (SOL-USD) fell 0.7%. Dogecoin (DOGE-USD) increased 0.7%, and Cardano (ADA-USD) advanced 0.6%.The US 10-year Treasury yield stood at 4.242% at 3 p.m. ET Friday, down from 4.305% Thursday, while the five-year yield fell to 3.836% from 3.911%.The total market value of the cryptocurrency industry rose 2.4% in the past 24 hours to $2.61 trillion, with trading volume gaining 2.6% to $158.98 billion.Price: $77363.53, Change: $+2211.54, Percent Change: +2.94%
Zai Lab (ZLAB) said Friday data from its ongoing phase 1 trial of zocilurtatug pelitecan showed a 53.7% intracranial objective response rate in patients with small cell lung cancer and brain metastases.The findings, which showed that the zoci drug candidate triggers intracranial lesion regression and reduced tumor size, will be presented at the American Association for Cancer Research Annual Meeting in San Diego, according to a statement.The potential zoci drug conjugate also demonstrated a manageable safety profile, with most adverse events reported as low grade, the company said.The company's phase 1b/2 trial data also showcased antitumor activity in patients with extrapulmonary neuroendocrine carcinomas, with an objective response rate of 38.2%, according to the company.Price: $24.06, Change: $+0.56, Percent Change: +2.38%
Palantir Technologies (PLTR), Thales, and Air Space Intelligence were selected by the US Federal Aviation Administration to compete on a new artificial intelligence tool for air traffic management, Bloomberg reported Friday, citing a person familiar with the matter.The FAA has received $12.5 billion from Congress for the project but it needs about $20 billion more to complete the overhaul, according to the report.Palantir did not immediately respond to a request for comment by.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $147.00, Change: $+4.24, Percent Change: +2.97%